PF-Atlas › Clinical Trials › NCT00198289
Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
Aurexis® · Phase 2
Registry ID
NCT00198289
Phase
Phase 2
Status
Completed
Drug / intervention
Aurexis® (tefibazumab)
Sponsor
Bristol-Myers Squibb
Start
2005-04
Enrollment
30
Locations
1
About this trial
Patients who are at least 7 years old with stable Cystic Fibrosis who have Staphylococcus aureus in their Lungs will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed until Study Day 57. Aurexis is a humanized monoclonal antibody that is designed to combat Staphylococcus aureus. The purpose of this study is to assess the safety and pharmacokinetic profile (concentration of Aurexis in blood and sputum) of Aurexis. Additionally, certain tests and measurements will be conducted to preliminarily determine if Aurexis demonstrates any benefit to these patients.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00198289 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.